Literature DB >> 23946593

Histopathology of type C liver disease for determining hepatocellular carcinoma risk factors.

Hiroshi Matsumura1, Kazushige Nirei, Hitomi Nakamura, Teruhisa Higuchi, Yasuo Arakawa, Masahiro Ogawa, Naohide Tanaka, Mitsuhiko Moriyama.   

Abstract

AIM: To evaluate the histopathological findings of type C liver disease to determine risk factors for development of hepatocellular carcinoma (HCC).
METHODS: We studied 232 patients, who underwent liver biopsy for type C chronic liver disease between 1992 and 2009, with sustained virological response (SVR) after interferon therapy. The patients were divided into two groups according to the F stage 0 + 1 + 2 group (n = 182) and F3 + 4 group (n = 50). We prospectively observed and compared the incidence of HCC of the patients with SVR in the F0 + 1 + 2 and F3 + 4 groups. Then, the background factors and liver histopathological findings, including the degree of fibrosis, F stage, inflammation, necrosis, bile duct obstruction, fat deposition, and degree of irregular regeneration (IR) of hepatocytes, were correlated with the risk of developing HCC.
RESULTS: HCC developed in three of 182 (1.6%) patients in the F0 + 1 + 2 group, and four of 50 (8.0%) in the F3 + 4 group. The cumulative incidence of HCC in the former group was found to be significantly lower than in the F3 + 4 group (log rank test P = 0.0224). The presence of atypical hepatocytes among IR of hepatocytes in the F3 + 4 group resulted in a higher cumulative incidence of HCC, and was significantly correlated with risk of HCC development (RR = 20.748, 95%CI: 1.335-322.5, P = 0.0303).
CONCLUSION: Atypical hepatocytes among the histopathological findings of type C liver disease may be an important risk factor for HCC development along with progression of liver fibrosis.

Entities:  

Keywords:  Hepatocellular carcinoma; Histopathology of liver biopsy; Irregular regeneration of hepatocytes; Liver fibrosis; Type C chronic liver disease

Mesh:

Substances:

Year:  2013        PMID: 23946593      PMCID: PMC3740418          DOI: 10.3748/wjg.v19.i30.4887

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  36 in total

1.  Irregular regeneration of hepatocytes is an important factor in the hepatocarcinogenesis of liver disease.

Authors:  Y Ueno; M Moriyama; T Uchida; Y Arakawa
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

2.  Irregular regeneration of hepatocytes and development of hepatocellular carcinoma in primary biliary cirrhosis.

Authors:  Hiroshi Miyakawa; Hirotoshi Fujikawa; Kentaro Kikuchi; Eriko Kitazawa; Yumi Kawashima
Journal:  Am J Gastroenterol       Date:  2002-02       Impact factor: 10.864

3.  Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy.

Authors:  Y Shiratori; F Imazeki; M Moriyama; M Yano; Y Arakawa; O Yokosuka; T Kuroki; S Nishiguchi; M Sata; G Yamada; S Fujiyama; H Yoshida; M Omata
Journal:  Ann Intern Med       Date:  2000-04-04       Impact factor: 25.391

Review 4.  Nonalcoholic steatohepatitis: definition and pathology.

Authors:  E M Brunt
Journal:  Semin Liver Dis       Date:  2001       Impact factor: 6.115

5.  Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach.

Authors:  C Cammà; M Giunta; P Andreone; A Craxì
Journal:  J Hepatol       Date:  2001-04       Impact factor: 25.083

6.  Pathomorphologic study on the mechanism of fatty change in small hepatocellular carcinoma of humans.

Authors:  R Kutami; Y Nakashima; O Nakashima; K Shiota; M Kojiro
Journal:  J Hepatol       Date:  2000-08       Impact factor: 25.083

Review 7.  Hepatocellular carcinoma in cirrhosis: incidence and risk factors.

Authors:  Giovanna Fattovich; Tommaso Stroffolini; Irene Zagni; Francesco Donato
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

Review 8.  Hepatocellular carcinoma: recent trends in Japan.

Authors:  Kendo Kiyosawa; Takeji Umemura; Tetsuya Ichijo; Akihiro Matsumoto; Kaname Yoshizawa; Amal Gad; Eiji Tanaka
Journal:  Gastroenterology       Date:  2004-11       Impact factor: 22.682

9.  Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis.

Authors:  R G Knodell; K G Ishak; W C Black; T S Chen; R Craig; N Kaplowitz; T W Kiernan; J Wollman
Journal:  Hepatology       Date:  1981 Sep-Oct       Impact factor: 17.425

Review 10.  HCV and oxidative stress in the liver.

Authors:  Alexander V Ivanov; Birke Bartosch; Olga A Smirnova; Maria G Isaguliants; Sergey N Kochetkov
Journal:  Viruses       Date:  2013-01-28       Impact factor: 5.048

View more
  5 in total

1.  Predisposing factors for hepatocellular carcinoma recurrence following initial remission after transcatheter arterial chemoembolization.

Authors:  Akitoshi Douhara; Tadashi Namisaki; Kei Moriya; Mitsuteru Kitade; Kosuke Kaji; Hideto Kawaratani; Kosuke Takeda; Yasushi Okura; Hiroaki Takaya; Ryuichi Noguchi; Norihisa Nishimura; Kenichiro Seki; Shinya Sato; Yasuhiko Sawada; Junichi Yamao; Akira Mitoro; Masakazu Uejima; Tsuyoshi Mashitani; Naotaka Shimozato; Soichiro Saikawa; Keisuke Nakanishi; Masanori Furukawa; Takuya Kubo; Hitoshi Yoshiji
Journal:  Oncol Lett       Date:  2017-06-28       Impact factor: 2.967

2.  Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients.

Authors:  Tarek K Motawi; Olfat G Shaker; Shohda A El-Maraghy; Mahmoud A Senousy
Journal:  PLoS One       Date:  2015-09-09       Impact factor: 3.240

Review 3.  Future of liver disease in the era of direct acting antivirals for the treatment of hepatitis C.

Authors:  Francesca Romana Ponziani; Francesca Mangiola; Cecilia Binda; Maria Assunta Zocco; Massimo Siciliano; Antonio Grieco; Gian Lodovico Rapaccini; Maurizio Pompili; Antonio Gasbarrini
Journal:  World J Hepatol       Date:  2017-03-08

4.  Steatosis influences the clinical profiles and long-term outcomes of interferon-treated chronic hepatitis C and liver cirrhosis patients.

Authors:  Kazushige Nirei; Hiroshi Matsumura; Mariko Kumakawa; Naoki Matsumoto; Hitomi Nakamura; Hiroaki Yamagami; Shunichi Matsuoka; Mitsuhiko Moriyama
Journal:  Int J Med Sci       Date:  2017-01-01       Impact factor: 3.738

5.  HCC incidence after hepatitis C cure among patients with advanced fibrosis or cirrhosis: A meta-analysis.

Authors:  Ian Lockart; Malcolm G H Yeo; Behzad Hajarizadeh; Gregory J Dore; Mark Danta
Journal:  Hepatology       Date:  2022-02-07       Impact factor: 17.298

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.